[LYWang (WeChat:ilieyun
) Beijing] Reported on February 10
Lieyun.com recently learned that YINJIA BIOSCIENCES, dedicated to developing upstream core raw materials and cutting-edge adjuvant therapeutic diagnostic products, has completed an angel financing round worth tens of millions of RMB. The round was led by CDH Investments, with participation from Furong Investment.
Dr. Wu Yifei, Founder, Chairman, and CEO of YINJIA BIOSCIENCES, stated: “We are deeply grateful to the two renowned domestic investment institutions for their support and trust. YINJIA BIOSCIENCES will leverage a suite of modern protein technologies—including computer simulation, AI-assisted design, and our proprietary CFPS (Cell-Free Protein Selective) technology—to build a comprehensive protein development platform. We aim to provide high-quality, difficult-to-replicate, highly stable, and cost-effective protein raw materials and reagents that benchmark against top international enterprises, serving clinical diagnostics, personalized medication guidance, new drug development, and other areas with unmet needs. Our goal is to become a high-tech platform company focused on multi-level protein applications, combining source innovation with internationally advanced collaborative development. With the funds from this financing round, YINJIA BIOSCIENCES will attract core talent and establish an innovative R&D and production base in China. We will develop core reagents for early cancer diagnosis and a series of critical protein raw materials that are currently heavily reliant on imports by domestic manufacturers and enjoy high market demand, thereby laying a solid foundation for the subsequent development and clinical trials of innovative diagnostic products centered on early cancer detection, adjuvant immunotherapy, and cell therapy.”
Dr. Liu Dan, Partner at CDH VGC (Innovation and Growth Fund), stated, “Protein raw materials with independent intellectual property rights and performance comparable to world-leading standards have become key to the independent innovation of China’s tumor diagnosis or immunotherapy technologies. Leveraging its proprietary unique protein optimization platform, CFPS, and other technologies, YINJIA BIOSCIENCES has established a protein R&D technology platform through deep collaborations with internationally leading scholars and research institutions. By means of independent innovation, joint development, or international licensing, the company develops and sells core key protein raw materials for the Chinese and even global markets, holding immense future potential. Dr. Wu Yifei is not only a rare managerial scientist in original protein R&D within China but also one of the earliest advocates of companion diagnostics and precision medicine in the industry. CDH will support YINJIA BIOSCIENCES in its continuous innovation, researching and developing leading, high-end, high-quality core key protein raw materials to meet unmet needs in China’s tumor diagnosis and immunotherapy technology fields, promote industry development, and continuously create social welfare.”
Dr. Sun Pengjun, Chairman of Furong Investment, stated, “Reagent raw materials hold significant strategic importance within the entire in vitro diagnostics (IVD) industry chain. Innovations in downstream clinical application technologies often require support at the raw material level. Indeed, the performance limits of certain core raw materials largely determine the upper bound of IVD system performance. Currently, China’s core raw material industry relies heavily on imports. The monopolistic position held by foreign manufacturers has kept costs persistently high, severely undermining the international competitiveness of Chinese enterprises. Furthermore, the inability to fully guarantee a continuous and stable supply of imported core raw materials poses a serious threat to the industrial security of the entire IVD sector. Furong Investment’s participation in the angel financing round of YINJIA BIOSCIENCES aims to leverage Dr. Wu Yifei’s team and their profound expertise in the companion diagnostics and precision medicine industries to pioneer new frontiers in the original research and development of proteins. We believe that, both in China and globally, this experienced team will emerge as a leader in protein R&D for tumor diagnostics or immunotherapy technologies through sustained innovative research and the continuous attraction of top global talent.”
According to information from the Tianyancha app, YINJIA BIOSCIENCES (Shanghai) Biopharmaceutical Technology Co., Ltd. was established in November 2020, with Wu Yifei serving as its legal representative. Dr. Wu Yifei, founder of YINJIA BIOSCIENCES, previously served as Vice President of WuXi AppTec and General Manager of the Clinical Diagnostics and Reagents Division. He earned his Ph.D. in Cell and Molecular Biology from the University of Michigan Medical School in the United States and has 18 years of overseas study and work experience. His industrial career abroad includes roles as a Senior Development Scientist for core diagnostic protein raw materials and immunoassay reagents at Roche Diagnostics in the U.S., and as a Senior Process Development Scientist for protein therapeutics at Cook Pharmica in the U.S.
After returning to China in early 2008, Dr. Wu Yifei successively held team leadership positions at companies including CrownBio (Beijing), Yangtze River Pharmaceutical Group, and Rendong Medicine. With many years of experience in the development, manufacturing, and project management of protein-based therapeutics and diagnostic products, as well as over a decade of collaborative engagements with more than 90 leading domestic and international pharmaceutical companies, biotechnology firms, and hospitals since his return, Dr. Wu has amassed extensive hands-on experience in operations management and regulatory oversight across both the pharmaceutical and diagnostic sectors.
In addition, the core team of YINJIA BIOSCIENCES is composed of overseas-educated PhDs and Masters with extensive experience in the development, production, and operational management of new drugs and diagnostic reagents at renowned pharmaceutical and diagnostic companies, as well as key technical, marketing, and sales professionals with substantial hands-on frontline work experience.
YINJIA BIOSCIENCES is a technology platform company focused on multi-level protein applications, committed to both source innovation and international collaborative development. By establishing in-depth partnerships with leading international scholars and research institutions, the company has built a protein R&D technology platform through independent innovation, joint development, and international licensing. It develops, manufactures, and sells core key protein raw materials and reagents for the Chinese and global markets. Furthermore, leveraging this platform, YINJIA BIOSCIENCES develops key core protein reagents targeting early tumor diagnosis, personalized medication guidance, adjunctive tumor immunotherapy, and cell therapy, thereby benefiting patients.
YINJIA BIOSCIENCES is registered in the Lingang New Area of the Shanghai Free Trade Zone, with its R&D center located in Shanghai, its production base in Suzhou Industrial Park, and an R&D and regulatory affairs center established in Beijing.